{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:15:52Z","timestamp":1785161752241,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.yexcr.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T11:03:28Z","timestamp":1560337408000},"page":"111466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3"],"prefix":"10.1016","volume":"382","author":[{"given":"Yanbing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yexcr.2019.06.011_bib1","first-page":"7","volume":"67","author":"Siegel","year":"2017","journal-title":"Ca - Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.yexcr.2019.06.011_bib2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.yexcr.2019.06.011_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MOU.0000000000000463","article-title":"Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma","volume":"28","author":"Weiss","year":"2018","journal-title":"Curr. Opin. Urol."},{"issue":"1","key":"10.1016\/j.yexcr.2019.06.011_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.critrevonc.2010.07.018","article-title":"Sequential use of targeted agents in the treatment of renal cell carcinoma","volume":"77","author":"Hutson","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.yexcr.2019.06.011_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian sirtuins: biological insights and disease relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu. Rev. Pathol."},{"issue":"4","key":"10.1016\/j.yexcr.2019.06.011_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ccr.2008.09.001","article-title":"Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice","volume":"14","author":"Wang","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.yexcr.2019.06.011_bib7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1245\/s10434-011-2159-4","article-title":"SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis","volume":"19","author":"Chen","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.yexcr.2019.06.011_bib8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.humpath.2015.03.015","article-title":"Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype","volume":"46","author":"Chung","year":"2015","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.yexcr.2019.06.011_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10585-015-9767-5","article-title":"Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer","volume":"33","author":"Chung","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.yexcr.2019.06.011_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/or.2015.4333","article-title":"MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma","volume":"35","author":"Zhang","year":"2016","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.yexcr.2019.06.011_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3727\/096504013X13775486749218","article-title":"MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma","volume":"21","author":"Liang","year":"2014","journal-title":"Oncol. Res."},{"issue":"1\u20132","key":"10.1016\/j.yexcr.2019.06.011_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-017-3102-1","article-title":"MiRNA-200a induce cell apoptosis in renal cell carcinoma by directly targeting SIRT1","volume":"437","author":"Fu","year":"2018","journal-title":"Mol. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.yexcr.2019.06.011_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.urolonc.2017.08.016","article-title":"Differential expression of the sirtuin family in renal cell carcinoma: aspects of carcinogenesis and prognostic significance","volume":"35","author":"Jeh","year":"2017","journal-title":"Urol. Oncol.: Semin. Orig. Invest."},{"issue":"6","key":"10.1016\/j.yexcr.2019.06.011_bib14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1159\/000362964","article-title":"Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by deubiquitinating SIRT1","volume":"33","author":"Ao","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"issue":"4","key":"10.1016\/j.yexcr.2019.06.011_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ncb1857","article-title":"STAT3 inhibition of gluconeogenesis is downregulated by SirT1[J]","volume":"11","author":"Nie","year":"2009","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.yexcr.2019.06.011_bib16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1073\/pnas.82.8.2344","article-title":"Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion","volume":"82","author":"Kant","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.yexcr.2019.06.011_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0021-9258(17)42404-5","article-title":"Overexpression of any fibrinogen chain by Hep G2 cells specifically elevates the expression of the other two chains","volume":"269","author":"Roy","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.yexcr.2019.06.011_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10753-011-9332-6","article-title":"Fibrinogen beta-chain-C148T poly -morphism is associated with increased fibrinogen, C-reactive protein, and interleukin-6 in patients undergoing coronary artery bypass grafting","volume":"35","author":"Wypasek","year":"2012","journal-title":"Inflammation"},{"issue":"16","key":"10.1016\/j.yexcr.2019.06.011_bib19","doi-asserted-by":"crossref","first-page":"10574","DOI":"10.1016\/S0021-9258(18)91001-X","article-title":"Fibrinogen precursors. Order of assembly of fibrinogen chains","volume":"259","author":"Yu","year":"1984","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.yexcr.2019.06.011_bib20","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/01.ATV.19.12.3063","article-title":"Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration","volume":"19","author":"van T Hooft","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.yexcr.2019.06.011_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006694","article-title":"Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"issue":"12","key":"10.1016\/j.yexcr.2019.06.011_bib22","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00432-017-2493-4","article-title":"Fibrinogen promotes malignant biological tumor behavior involving epithelial\u2013mesenchymal transition via the p-AKT\/p-mTOR pathway in esophageal squamous cell carcinoma","volume":"143","author":"Zhang","year":"2017","journal-title":"J. Cancer Res. Clin."},{"issue":"5","key":"10.1016\/j.yexcr.2019.06.011_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/jso.21668","article-title":"High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer","volume":"102","author":"Tang","year":"2010","journal-title":"J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.yexcr.2019.06.011_bib26","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3892\/ol.2017.6328","article-title":"Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer","volume":"14","author":"Du","year":"2017","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1464-410X.2012.11653.x","article-title":"Tumour expression of bladder cancer-associated urinary proteins","volume":"112","author":"Linden","year":"2013","journal-title":"BJU Int."},{"issue":"10","key":"10.1016\/j.yexcr.2019.06.011_bib28","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood.V96.10.3302","article-title":"Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells","volume":"96","author":"Palumbo","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.yexcr.2019.06.011_bib29","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V86.5.1802.bloodjournal8651802","article-title":"Cell proliferation on fibrin: modulation by fibrinopeptide cleavage","volume":"86","author":"Sporn","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ijc.24340","article-title":"The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells","volume":"125","author":"Sahni","year":"2009","journal-title":"Int. J. Ccancer"},{"key":"10.1016\/j.yexcr.2019.06.011_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9591506","article-title":"Clinical and prognostic effect of plasma fibrinogen in renal cell carcinoma: a meta-analysis","author":"Tian","year":"2017","journal-title":"BioMed Res. Int."},{"issue":"4","key":"10.1016\/j.yexcr.2019.06.011_bib32","article-title":"Preoperative plasma fibrinogen level as a significant prognostic factor in patients with localized renal cell carcinoma after surgical treatment","volume":"95","author":"Lee","year":"2016","journal-title":"Medcine"},{"issue":"4","key":"10.1016\/j.yexcr.2019.06.011_bib33","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bju.13414","article-title":"Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma","volume":"118","author":"Obata","year":"2016","journal-title":"BJU Int."},{"issue":"8","key":"10.1016\/j.yexcr.2019.06.011_bib36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jclinpath-2012-200685","article-title":"Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma","volume":"65","author":"Jang","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691180","article-title":"SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells","volume":"39","author":"Jin","year":"2017","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.yexcr.2019.06.011_bib38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1538-7836.2006.01861.x","article-title":"Fibrin structure and wound healing","volume":"4","author":"Laurens","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.yexcr.2019.06.011_bib39","first-page":"932","article-title":"Fibrinogen and fibrin structure and functions","volume":"4","author":"Mosesson","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.yexcr.2019.06.011_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00281-011-0290-8","article-title":"Fibrinogen as a key regulator of inflammation in disease","volume":"34","author":"Davalos","year":"2012","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/01443615.2015.1065231","article-title":"Endometrial cancer cells can express fibrinogen: immuno -histochemistry and RT-PCR analysis","volume":"36","author":"Uccella","year":"2016","journal-title":"J. Obstet. Gynaecol."},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0038-1650298","article-title":"Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells","volume":"75","author":"Lee","year":"1996","journal-title":"Thromb. Haemostasis"},{"issue":"19","key":"10.1016\/j.yexcr.2019.06.011_bib44","doi-asserted-by":"crossref","first-page":"14116","DOI":"10.1016\/S0021-9258(19)85216-X","article-title":"Evidence for an acute phase response in human intestinal epithelial cells","volume":"268","author":"Molmenti","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.yexcr.2019.06.011_bib45","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1128\/IAI.66.9.4431-4439.1998","article-title":"Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia","volume":"66","author":"Simpson-Haidaris","year":"1998","journal-title":"Infect. Immun."},{"issue":"11","key":"10.1016\/j.yexcr.2019.06.011_bib46","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3748\/wjg.v20.i11.3025","article-title":"Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis","volume":"20","author":"He","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.yexcr.2019.06.011_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ncb1857","article-title":"STAT3 inhibition of gluconeogenesis is downregulated by SirT1","volume":"11","author":"Nie","year":"2009","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0962-8924(99)01709-2","article-title":"Association of STATs with relatives and friends","volume":"10","author":"Chatterjee-Kishore","year":"2000","journal-title":"Trends Cell Biol."},{"issue":"11","key":"10.1016\/j.yexcr.2019.06.011_bib49","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.yexcr.2019.06.011_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.oraloncology.2015.03.004","article-title":"Review of STAT3 (signal transducers and activators of transcription) in head and neck cancer","volume":"51","author":"Mali","year":"2015","journal-title":"Oral Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2019.06.011_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2220\/biomedres.30.171","article-title":"Is Stat3 and\/or p53 mRNA expression a prognostic marker for renal cell carcinoma?","volume":"30","author":"Masuda","year":"2009","journal-title":"Biomed. Res."},{"key":"10.1016\/j.yexcr.2019.06.011_bib52","doi-asserted-by":"crossref","first-page":"17663","DOI":"10.1038\/srep17663","article-title":"Multiple regulation pathways and pivotal biological functions of STAT3 in cancer","volume":"5","author":"Yuan","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719303064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719303064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:24:31Z","timestamp":1757996671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482719303064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0014482719303064"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.06.011","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111466"}}